Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma

Phase 1b, open-label study evaluating the safety, tolerability, pharmacokinetics, preliminary antitumor activity, and pharmacodynamics of OPN-6602 monotherapy and in combination with dexamethasone in subjects with relapsed and/or refractory MM.

Trial Details

NCT ID
NCT06433947
Phase
PHASE1
Sponsor
Opna Bio LLC
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • OPN-6602
  • Dexamethasone
Locations (sample)
  • Gilbert, Arizona, United States|33.35283,-111.78903
  • La Jolla, California, United States|32.84727,-117.2742
  • Stanford, California, United States|37.42411,-122.16608
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Westwood, Kansas, United States|39.04056,-94.6169

Key Eligibility Criteria

  • Confirmed diagnosis of multiple myeloma (MM)
  • Relapsed or refractory to 3 or more different prior lines of therapy for MM that included immunomodulatory agents, proteosome inhibitors, and anti-…
  • Adequate hematologic, renal, liver, cardiac function

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →